Illumina Officials Say Array Business Will Benefit from Epicentre Buy
February 15, 2011
Illumina Officials Say Array Business Will Benefit from Epicentre Buy
CEO Jay Flatley said Illumina has in the past licensed "several" Epicentre enzymes for use in its array business. Now the company has the "ability to use those enzymes at cost rather than [retail] price."
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- New Product Watch
November 9, 2010 / BioArray News - Fluidigm to Launch SNP Panel Designed to Help Biorepositories QC and ID Their Sample Collections
April 23, 2013 / BioArray News - Q&A: RUCDR's Andy Brooks on the Challenges Facing Biorepositories and the Rise of Biobank Arrays
April 23, 2013 / BioArray News - People in the News: Matt Posard
April 2, 2013 / BioArray News - Affy Files CytoScan with FDA, Plans 'Aggressive' Marketing Campaign to Grow Cyto Business
February 19, 2013 / BioArray News